Market Size of H1N1 Vaccines Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 5.20 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
H1N1 Vaccines Market Analysis
The H1N1 Vaccines Market is expected to register a CAGR of 5.2% during the forecast period. The H1N1 virus, commonly known as swine flu is an infectious disease in humans caused by the swine H1N1 virus, which is characterized by a persistent cough, cold, high fever, red watery eyes, body aches, headache, and general discomfort. H1N1 virus affects various species such as swine, birds, horses and other animals. The H1N1 virus is contagious and can spread widely through small droplets of saliva from coughs or sneezes of infected person. H1N1 virus causes damage to the respiratory system including nose, lungs, and throat. The H1N1 virus is a Ribonucleic acid (RNA) virus belonging to the Orthomyxoviridae family. In the year 2009, a strain of swine flu called "H1N1" infected many people around the world.
According to the World Health Organization (WHO), annually about 3 to 5 million cases of severe illness and about 2,90,000 to 6,50,000 respiratory deaths are due to seasonal influenza. In the case of industrialized countries, most of the deaths due to influenza occur among people above 65 years of age. Seasonal influenza illnesses range from mild to severe and even death.
Increasing incidences of epidemic H1N1 infection and declining immunity among the geriatric population and technological advancements in the vaccines are the key driving factors in the H1N1 vaccines market.